Skip to main content

NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Astrocytoma Clinical Trials

Review the astrocytoma clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 35

Testing the Addition of an Anti-cancer Drug, Vorasidenib, to the Usual Treatment, Temozolomide, After Radiation Therapy for Advanced Brain Cancer
Status: Active
Location: 170 locations
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients with Low-Grade Glioma
Status: Active
Location: 118 locations
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Status: Active
Location: 49 locations
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Status: Active
Location: 37 locations
Adjuvant 177Lu-PSMA-617 Radiopharmaceutical Therapy with Temozolomide for the Treatment of IDH Wild Type Gliomas Expressing PSMA following Standard Treatment
Status: Active
Location: 7 locations
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
Status: Active
Location: 5 locations
Study of Olutasidenib and Temozolomide in HGG
Status: Active
Location: 6 locations
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Status: Active
Location: 6 locations
Oncolytic HSV-1 G207 in Patients with Recurrent or Refractory Cerebellar Brain Tumors
Status: Active
Location: 4 locations
DB107-RRV in Combination with DB107-FC for the Treatment of Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma
Status: Active
Location: 3 locations
Ex Vivo Expanded CD34+ Hematopoietic Stem Cells in Combination with Nivolumab for the Treatment of Recurrent, Progressive, or Refractory Pediatric High-grade Glioma
Status: Active
Location: 3 locations
Peginterferon alfa-2b in Treating Younger Patients with Recurrent or Refractory and Radiographically or Clinically Progressive Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Active
Location: 2 locations
A Vaccine (RNA-LP) for the Treatment of Recurrent Pediatric High-Grade Glioma and Recurrent Osteosarcoma, RNA PRIME Trial
Status: Active
Location: 2 locations
Intra-arterial Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treating Patients Under 22 Years of Age with Relapsed or Refractory Intracranial Glioma
Status: Active
Location: 2 locations
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Tretinoin and Retifanlimab in Treating Patients with Recurrent IDH-Mutant Glioma
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
GI-102 Alone or in Combination with Pembrolizumab before Surgery for the Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Mirdametinib for the Treatment of Low-Grade Glioma
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
PCI-24781 in Combination with Temozolomide for the Treatment of High Grade Glioma
Status: Active
Location: University of Nebraska Medical Center, Omaha, Nebraska
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive, IDH-Wildtype, Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Engineered NK Cells Containing Deleted TGF-BetaR2 and NR3C1 for the Treatment of Recurrent Grade 4 Recurrent Astrocytoma
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
MSC-DNX-2401 in Treating Patients with Recurrent High-Grade Glioma
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
SRN-101 for the Treatment of Patients Undergoing Surgery for Recurrent High-Grade Glioma
Status: Active
Location: University of California San Francisco, San Francisco, California